TABLE 2.
Summary of Bmax values for specific [3H]nisoxetine binding in SERT+/+, SERT+/−, and SERT−/− mice
Data are expressed as means ± S.E.M. in femtomoles per milligram protein.
| Genotype | P21 | P28 | P90 |
|---|---|---|---|
| Prefrontal cortex | |||
| SERT+/+ | 228 ± 23* | 275 ± 26 | 314 ± 36 |
| SERT+/− | 229 ± 23 | 251 ± 21 | 290 ± 30 |
| SERT−/− | 206 ± 19 | 271 ± 35 | 225 ± 26 |
| Amygdala | |||
| SERT+/+ | 193 ± 27 | 137 ± 14* | 233 ± 29 |
| SERT+/− | 150 ± 29 | 165 ± 14 | 191 ± 24 |
| SERT−/− | 157 ± 24 | 146 ± 20 | 155 ± 21 |
| Dorsal raphe | |||
| SERT+/+ | 619 ± 40 | 551 ± 35 | 539 ± 35 |
| SERT+/− | 560 ± 57 | 562 ± 31 | 578 ± 27 |
| SERT−/− | 565 ± 20 | 543 ± 24 | 536 ± 36 |
Sample sizes of mice per group were as follows: SERT+/+, n = 5–9 mice per group (4 males and 3–5 females, pooled); SERT+/−, n = 6–10 (3–5 males and 2–4 females, pooled); and SERT−/−, n = 4–7 (2–4 males and 2–4 females, pooled).
*
P < 0.05 (different from SERT genotype–matched P90 group; Dunnett multiple comparisons test after two-factor ANOVA).